Azithromycin

Where the papers sit

10 papers from the last 6 months study azithromycin directly · updated from PubMed 5 Oct 2026

• Respiratory Antibiotic Care

  Azithromycin is being evaluated across pediatric wheezing, uncontrolled asthma, COPD exacerbations, and Mycoplasma pneumoniae infection, with no single clinical direction yet. Studies address epithelial antiviral immunity and comparative effectiveness alongside doxycycline and roflumilast. Resistance, including an rplV insertion in Rickettsia typhi, remains a recurring concern. QT prolongation adds a separate safety question, leaving this cluster broad rather than unified.

  6 papers · 60%

• Pseudomonas Infection Treatment

  Pulmonary Pseudomonas aeruginosa treatment is moving toward targeted delivery and antibiotic potentiation. Trojan horse azithromycin derivatives aim to improve bacterial uptake, while nano-in-micro powders pair azithromycin with menadione as an adjuvant. Both approaches address difficult pulmonary infection rather than simple drug substitution. Their clinical value remains open pending evidence beyond formulation and preclinical testing.

  2 papers · 20%

• Wound Biofilm Eradication

  Local engineered therapies are being developed to clear bacterial biofilms while supporting wound healing. Iontophoresis and magnesium oxide fiber films deliver azithromycin at the wound, whereas enzyme-powered PLGA micromotors attack biofilm biomass and limit regrowth. The recurring endpoint is durable Staphylococcus aureus biofilm control rather than transient killing. Translation will depend on sustained activity, tissue compatibility, and performance in complex wounds.

  2 papers · 20%